Read by QxMD icon Read

Breast Cancer: Basic and Clinical Research

David N Danforth
Sporadic breast cancer develops through the accumulation of molecular abnormalities in normal breast tissue, resulting from exposure to estrogens and other carcinogens beginning at adolescence and continuing throughout life. These molecular changes may take a variety of forms, including numerical and structural chromosomal abnormalities, epigenetic changes, and gene expression alterations. To characterize these abnormalities, a review of the literature has been conducted to define the molecular changes in each of the above major genomic categories in normal breast tissue considered to be either at normal risk or at high risk for sporadic breast cancer...
2016: Breast Cancer: Basic and Clinical Research
Ragıp Kayar, Özgül V Çilengiroğlu
[This corrects the article on p. 87 in vol. 9, PMID: 26691819.].
2016: Breast Cancer: Basic and Clinical Research
Angela Pennisi, Thomas Kieber-Emmons, Issam Makhoul, Laura Hutchins
Breast cancer is a heterogeneous disease, and the different biological subtypes have different prognostic impacts. Neoadjuvant trials have recently become popular as they offer several advantages compared to traditional adjuvant trials. Studies have shown that patients who achieve pathological complete response (pCR) after neoadjuvant treatment have a better long-term outcome. Consequently, increasing the rate of pCR became the end point of neoadjuvant trials with the expectation of translation into improved survival...
2016: Breast Cancer: Basic and Clinical Research
Meaghan Krohe, Yanni Hao, Roger E Lamoureux, Nina Galipeau, Denise Globe, Catherine Foley, Iyar Mazar, Jeffrey Solomon, Alan L Shields
INTRODUCTION: Patient-reported outcome (PRO) measures serve to capture vital patient information not otherwise obtained by primary study endpoints. This paper examines how PROs are utilized as endpoints in industry-sponsored metastatic breast cancer clinical trials. METHODS: A search was conducted in the web site for trials involving common treatments for metastatic breast cancer. Thirty-eight clinical trials were identified which included a PRO endpoint in the study, and data were extracted and summarized...
2016: Breast Cancer: Basic and Clinical Research
Maryam Rezaei, Mohammad Hashemi, Sara Sanaei, Mohammad Ali Mashhadi, Mohsen Taheri
Breast cancer (BC) is one of the most causes of death in women worldwide. It affects Iranian female population approximately a decade earlier than those in other parts of the world. Previous studies have shown that vascular endothelial growth factor (VEGF) gene variants were associated with BC risk. The current study aimed to evaluate the impact of VEGF rs3025039 (+936C>T), rs2010963 (+405C>G), rs833061 (-460T>C), rs699947 (-2578C>A), and rs35569394 (18-bp I/D) polymorphisms on BC risk in an Iranian population in southeast of Iran...
2016: Breast Cancer: Basic and Clinical Research
Chris Twelves, Ahmad Awada, Javier Cortes, Louise Yelle, Galina Velikova, Martin S Olivo, James Song, Corina E Dutcus, Peter A Kaufman
PURPOSE AND METHODS: Our secondary analyses compared survival with eribulin versus capecitabine in various patient subgroups from a phase 3, open-label, randomized study. Eligible women aged ≥18 years with advanced/metastatic breast cancer and ≤3 prior chemotherapies (≤2 for advanced/metastatic disease), including an anthracycline and taxane, were randomized 1:1 to intravenous eribulin mesylate 1.4 mg/m(2) on days 1 and 8 or twice-daily oral capecitabine 1250 mg/m(2) on days 1-14 (21-day cycles)...
2016: Breast Cancer: Basic and Clinical Research
Manju Bala Popli, Pranav Gupta, Devraj Arse, Pawan Kumar, Prabhjot Kaur
OBJECTIVE: The purpose of this research work was to evaluate complex cystic breast lesions by advanced MRI techniques and correlating imaging with histologic findings. METHODS AND MATERIALS: In a cross-sectional design from September 2013 to August 2015, 50 patients having sonographically detected complex cystic lesions of the breast were included in the study. Morphological characteristics were assessed. Dynamic contrast-enhanced MRI along with diffusion-weighted imaging and MR spectroscopy were used to further classify lesions into benign and malignant categories...
2016: Breast Cancer: Basic and Clinical Research
Tyler J Kochel, Olga G Goloubeva, Amy M Fulton
Elevated levels of cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) are indicators of a poor prognosis in breast cancer. Using several independent publicly available breast cancer gene expression databases, we investigated other members of the PGE2 pathway. PGE2 is produced by COX-2 and actively exported by multiple drug resistance-associated protein 4 (MRP4) into the extracellular microenvironment, where PGE2 can bind four cognate EP receptors (EP1-EP4) and initiate diverse biological signaling pathways...
2016: Breast Cancer: Basic and Clinical Research
Som D Mukherjee, Nicole Hodgson, Peter J Lovrics, Kavita Dhamanaskar, Terry Minuk, Shelley Chambers, Jonathan Sussman
INTRODUCTION: Breast magnetic resonance imaging (MRI) is considered a more sensitive diagnostic test for detecting invasive breast cancer than mammography or breast ultrasound. Breast MRI may be particularly useful in younger premenopausal women with higher density breast tissue for differentiating between dense fibroglandular breast tissue and breast malignancies. The main objective of this study was to determine the impact of preoperative breast MRI on surgical decision-making in young women with breast cancer...
2016: Breast Cancer: Basic and Clinical Research
K Mungrue, H Chase, J Gordon, D Knowles, K Lockhart, N Miller, T Morley, L Sealey, B Turner
BACKGROUND: Breast cancer is the most common form of cancer affecting women in the Bahamas, which consists of many islands. This is the first attempt to identify which island has the highest occurrence of breast cancer. OBJECTIVE: The aim of this study was to describe the sociodemographical and spatial features of breast cancer in the Bahamas in 2009-2011. METHODS: A review of the medical records of all women with a confirmed diagnosis of breast cancer during the period January 1, 2009-December 31, 2011, was undertaken...
2016: Breast Cancer: Basic and Clinical Research
Vittorio Pasta, Simona Dinicola, Alessandro Giuliani, Abdel Halim Harrath, Saleh H Alwasel, Francesco Tartaglia, Alessandra Cucina, Mariano Bizzarri
Benign mammary lumps and mastalgia are the most common breast disorders; yet, there is no clear-cut consensus about the best strategy for their treatment. We hypothesized that a combination, including boswellic acid, betaine, and myoinositol, would be beneficial in breast disorders by exerting a pleiotropic effect on multiple pathways. Indeed, myoinositol has already been proven to modulate some factors involved in the genesis of breast diseases, such as fibrosis and metabolic and endocrine cues. In our study, 76 women were randomly assigned to either the experimental or the placebo arm...
2016: Breast Cancer: Basic and Clinical Research
Simon B Zeichner, Hiromi Terawaki, Keerthi Gogineni
Patients with breast cancer along with metastatic estrogen and progesterone receptor (ER/PR)- and human epidermal growth factor receptor 2 (HER2)-negative tumors are referred to as having metastatic triple-negative breast cancer (mTNBC) disease. Although there have been many new treatment options approved by the Food and Drug Administration for ER/PR-positive and Her2/neu-amplified metastatic breast cancer, relatively few new agents have been approved for patients with mTNBC. There have been several head-to-head chemotherapy trials performed within the metastatic setting, and much of what is applied in clinical practice is extrapolated from chemotherapy trials in the adjuvant setting, with taxanes and anthracyclines incorporated early on in the patient's treatment course...
2016: Breast Cancer: Basic and Clinical Research
Joelle Zambrano, Elizabeth S Yeh
While breast cancer patients benefit from the use of HER2 inhibitors, many fail therapy and become resistant to treatment, indicating a critical need to prevent treatment failure. A number of studies have emerged that highlight the catabolic process of autophagy in breast cancer as a mechanism of resistance to chemotherapy and targeted inhibitors. Furthermore, recent research has begun to dissect how autophagy signaling crosstalks with apoptotic signaling. Thus, a possible strategy in fighting resistance is to couple targeting of apoptotic and autophagy signaling pathways...
2016: Breast Cancer: Basic and Clinical Research
Ana de la Torre, Kirenia Pérez, Aliz M Vega, Eduardo Santiesteban, Raiza Ruiz, Leonardo Hernández, Dayamí Durrutí, Carmen E Viada, Liset Sánchez, Mabel Álvarez, Yunier Durán, Yoisbel G Moreno, Maylén Arencibia, Meylán Cepeda, Milagros Domecq, Leticia Cabrera, Jorge L Sánchez, José J Hernández, Ana R Valls, Luis E Fernández
NGcGM3 ganglioside is a tumor-specific antigen expressed in human breast tumors. The NGcGM3/VSSP vaccine, consisting in very small-sized proteoliposomes (VSSP) obtained by the incorporation of NGcGM3 into the outer membrane protein complex of Neisseria meningitidis, has been previously tested in a Phase II trial in patients with metastatic breast cancer (MBC) but emulsified with Montanide ISA 51. An Expanded Access study was carried out in MBC patients aiming to find if a nonemulsive formulation of NGcGM3/VSSP, without Montanide ISA 51, could be more safe and effective...
2016: Breast Cancer: Basic and Clinical Research
Adrien Albert, Ivan Huyghe, Sigrid Stroobants, Wiebren A A Tjalma
A local breast cancer recurrence or a new breast cancer in the previously treated breast is a staging challenge. Staging is important to tailor the local and the systemic treatment. Earlier treatment(s) can disrupt the primary lymphatic drainage. After the disruption, new lymphatic drainage pathways are often created. The identification of these new pathways together with their sentinel node(s) (SN) is important for retreatment. A fluorodeoxyglucose positron emission tomography-computerized tomography could be useful to identify the involved node(s), but, unfortunately, there is no evidence to support this...
2016: Breast Cancer: Basic and Clinical Research
Venkata Ramana Kotamraju, Shweta Sharma, Poornima Kolhar, Lilach Agemy, James Pavlovich, Erkki Ruoslahti
Tumor-homing peptides with tissue-penetrating properties increase the efficacy of targeted cancer therapy by delivering an anticancer agent to the tumor interior. LyP-1 (CGNKRTRGC) and iRGD (CRGDKGPDC) are founding members of this class of peptides. The presence of the cysteines forming the cyclizing disulfide bond complicates conjugation of these peptides with other molecules, such as drugs. Here, we report the synthesis of conjugatable disulfide-bridged peptides and their conjugation to biologically important molecules...
2015: Breast Cancer: Basic and Clinical Research
Wes E Kim, Binbin Yue, Ginette Serrero
Her2 is a receptor tyrosine kinase overexpressed in 25% of breast tumors. We have shown that the 88 kDa autocrine growth and survival factor GP88 (progranulin) stimulated Her2 phosphorylation and proliferation and conferred Herceptin resistance in Her2-overexpressing cells. Herein, we report that GP88 stimulates c-myc phosphorylation and upregulates c-myc levels in Her2-overexpressing cells. c-myc phosphorylation and upregulation by GP88 were not observed in non-Her2-overexpressing breast cancer cells. c-myc activation was inhibited upon treatment with ERK, PI3 kinase, and c-src pathway inhibitors, U0126, LY294002, and PP2...
2015: Breast Cancer: Basic and Clinical Research
Khadidiatou Guiro, Treena L Arinzeh
Despite substantial advances in early diagnosis, breast cancer (BC) still remains a clinical challenge. Most BC models use complex in vivo models and two-dimensional monolayer cultures that do not fully mimic the tumor microenvironment. The integration of cancer biology and engineering can lead to the development of novel in vitro approaches to study BC behavior and quantitatively assess different features of the tumor microenvironment that may influence cell behavior. In this review, we present tissue engineering approaches to model BC in vitro...
2015: Breast Cancer: Basic and Clinical Research
Jamila Al-Azhri, Tulay Koru-Sengul, Feng Miao, Constantine Saclarides, Margaret M Byrne, Eli Avisar
PURPOSE: Despite the established guidelines for breast cancer treatment, there is still variability in surgical treatment after neoadjuvant therapy (NT) for women with large breast tumors. Our objective was to identify predictors of the type of surgical treatment: mastectomy versus breast-conserving surgery (BCS) in women with T3/T4 breast cancer who received NT. METHODS: Population-based Florida Cancer Data System Registry, Florida's Agency for Health Care Administration, and US census from 1996 to 2009 were linked for women diagnosed with T3/T4 breast cancer and received NT followed by either BCS or mastectomy...
2015: Breast Cancer: Basic and Clinical Research
Ragıp Kayar, Özgül V Çilengiroğlu
AIM: The aim of this study was to investigate the criteria for determining the cancer risk of the breast asymmetry by comparing breast volume asymmetry levels between healthy women and women with cancer. MATERIALS AND METHODS: Two hundred and one women with breast cancer (group 1) were compared with 446 healthy women (group 2) who had no pathologic findings in breast sonography and mammograpy repeated with one-year interval. Data were evaluated retrospectively. Each breast volume was measured twice by Grossman-Roudner Discs...
2015: Breast Cancer: Basic and Clinical Research
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"